🇯🇵 Beta-D-N4-Hydroxycytidine in Japan

PMDA authorised Beta-D-N4-Hydroxycytidine on 24 December 2021

Marketing authorisation

PMDA — authorised 24 December 2021

  • Marketing authorisation holder: MSD K.K.
  • Status: approved

Beta-D-N4-Hydroxycytidine in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Metabolic approved in Japan

Frequently asked questions

Is Beta-D-N4-Hydroxycytidine approved in Japan?

Yes. PMDA authorised it on 24 December 2021.

Who is the marketing authorisation holder for Beta-D-N4-Hydroxycytidine in Japan?

MSD K.K. holds the Japanese marketing authorisation.